Arrowhead Pharmaceuticals (ARWR) Non Operating Investment Income (2011)
Arrowhead Pharmaceuticals (ARWR) posted Non Operating Investment Income of -$58091.0 for Q4 2011, up 52.67% on a QoQ basis from -$122733.0 in Q3 2011.
Arrowhead Pharmaceuticals (ARWR) Non Operating Investment Income (2011) Analysis & Trends
Arrowhead Pharmaceuticals' Non Operating Investment Income history runs 1 years deep, the most recent figure standing at -$58091.0 for Q4 2011.
- Quarterly Non Operating Investment Income changed N/A year-over-year to -$58091.0 in Q4 2011, while the trailing twelve-month figure through Sep 2012 was -$58091.0 (changed N/A YoY) and the FY2012 annual result came in at -$58091.0, up 77.76% from the prior year.
- Non Operating Investment Income was -$58091.0 for Q4 2011 at Arrowhead Pharmaceuticals, up from -$122733.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $359920.0 in Q1 2011 and bottomed at -$498406.0 in Q2 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Arrowhead Pharmaceuticals | 12.26 Bn | 10.47 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2011 | -58,091.00 |
| Dec 31, 2011 | -58,091.00 |
| Sep 30, 2011 | -122,733.00 |
| Sep 30, 2011 | -122,733.00 |
| Jun 30, 2011 | -498,406.00 |
| Jun 30, 2011 | -498,406.00 |
| Mar 31, 2011 | 359,920.00 |
| Mar 31, 2011 | 359,920.00 |